COMMUNIQUÉS West-GlobeNewswire
-
Disc Medicine to Participate in Upcoming Investor Conferences
24/02/2026 -
NewGen Provides Recap of Strategic Progress as Diversification Fuels Success, Positions Company for Breakout Year
24/02/2026 -
The Uniqueness of Dr Allen’s Devices for Prostate, Kidneys and Low Back Pain Treatment Unveiled Worldwide
24/02/2026 -
Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market
24/02/2026 -
Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston
24/02/2026 -
24/7 Market News- “Somewhere in Michigan”: National Geographic Spotlights Kraig Biocraft Laboratories Science Powering Recombinant Spider Silk Production
24/02/2026 -
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery
24/02/2026 -
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference
24/02/2026 -
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
24/02/2026 -
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
24/02/2026 -
Apogee Therapeutics to Participate in Upcoming March Conferences
24/02/2026 -
Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next‑Generation Therapies for Obesity and Metabolic Diseases
24/02/2026 -
Paratek Pharmaceuticals Announces Positive Results for NUZYRA® Therapeutic Efficacy Studies in Inhalation Anthrax Triggering Additional Procurement under BARDA Project BioShield Contract
24/02/2026 -
Glass House Brands Board of Directors Establishes Product Expansion Committee to Support New Product and Business Development
24/02/2026 -
Porosome Therapeutics Announces New Porosome-Targeted Medicines Developed Using AI
24/02/2026 -
Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
24/02/2026 -
Promatix Biosciences Presents Positive Preclinical Data with First-in-Class PBS293 EGFR×EphA2 Cis-Bispecific ADC Demonstrating Enhanced Tumour Selectivity
24/02/2026 -
Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples
24/02/2026 -
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution
24/02/2026
Pages